Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine A Grosset

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Lancet (London, England)|June 9, 2004
Pergolide in Parkinson's disease: time for a change?Katherine A Grosset, Donald G Grosset
BMC Neurology|July 20, 2007
Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trialKatherine A Grosset, Donald G Grosset
Clinical Therapeutics|September 23, 2006
Proposed dose equivalence for rapid switching between dopamine agonists in Parkinson's diseaseKatherine A Grosset, Donald G Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|February 19, 2005
Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of lifeKatherine A Grosset, Donald G Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|July 23, 2005
Suboptimal medication adherence in Parkinson's diseaseKatherine A Grosset, Ian Bone, Donald G Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|August 11, 2005
Medicine-taking behavior: implications of suboptimal compliance in Parkinson's diseaseKatherine A Grosset, John L Reid, Donald G Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|November 21, 2008
Geographical difference in Parkinson's disease prevalence within West ScotlandEdward J Newman, Katherine A Grosset, Donald G Grosset
Journal of Rehabilitation Medicine|October 18, 2014
Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 casesDonald G Grosset, Elaine G Tyrrell, Katherine A Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2016
Nonmotor symptoms in patients without evidence of dopaminergic deficitDiane M A Swallow, Katherine A Grosset, Donald G Grosset
Journal of Parkinson'S Disease|August 14, 2013
Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group studyKatherine A Grosset, Naveed Malek, Frazer Morgan, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Lancet (London, England)|June 9, 2004
Pergolide in Parkinson's disease: time for a change?Katherine A Grosset, Donald G Grosset
BMC Neurology|July 20, 2007
Effect of educational intervention on medication timing in Parkinson's disease: a randomized controlled trialKatherine A Grosset, Donald G Grosset
Clinical Therapeutics|September 23, 2006
Proposed dose equivalence for rapid switching between dopamine agonists in Parkinson's diseaseKatherine A Grosset, Donald G Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|February 19, 2005
Patient-perceived involvement and satisfaction in Parkinson's disease: effect on therapy decisions and quality of lifeKatherine A Grosset, Donald G Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|July 23, 2005
Suboptimal medication adherence in Parkinson's diseaseKatherine A Grosset, Ian Bone, Donald G Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|August 11, 2005
Medicine-taking behavior: implications of suboptimal compliance in Parkinson's diseaseKatherine A Grosset, John L Reid, Donald G Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|November 21, 2008
Geographical difference in Parkinson's disease prevalence within West ScotlandEdward J Newman, Katherine A Grosset, Donald G Grosset
Journal of Rehabilitation Medicine|October 18, 2014
Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 casesDonald G Grosset, Elaine G Tyrrell, Katherine A Grosset
Movement Disorders : Official Journal of the Movement Disorder Society|February 20, 2016
Nonmotor symptoms in patients without evidence of dopaminergic deficitDiane M A Swallow, Katherine A Grosset, Donald G Grosset
Journal of Parkinson'S Disease|August 14, 2013
Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group studyKatherine A Grosset, Naveed Malek, Frazer Morgan, et al.
Pageof 4